Gavreto (pralsetinib)

pCPA File Number: 22032

Negotiation Status:

Concluded without agreement

Indication(s):

For the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC)

Sponsor/Manufacturer:

Hoffmann-La Roche Limited

CADTH Project Number:

PC0283

pCPA Engagement Letter Issued:

2023-06-12

Negotiation Process Concluded:

2023-07-24